http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 07:00:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Oncolytics+Biotech+%28ONCY%29/26764610.html <p>H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $10.00 price target on Oncolytics Biotech (NASDAQ: ONCY).</p><p>The analyst commented: "On July 13, Oncolytics provided a clinical and regulatory update on REO 033, its randomized controlled study of pelareorep (pela) plus FOLFIRI (irinotecan and 5- fluorouracil chemotherapy) and bevacizumab (an anti-VEGF monoclonal antibody, mAb) in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Oncolytics reported rapid operational progress in Part A (n=60), with roughly half of planned clinical sites activated by the end of July, more than 20 patients already pre-identified across participating centers, and the remaining sites expected online http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Oncolytics+Biotech+%28ONCY%29/26764610.html Tue, 14 Jul 2026 07:00:16 -0400 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+13/26760696.html si-local-file:///var/storage/secattach/20260713/26760696.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+13/26760696.html Mon, 13 Jul 2026 09:04:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+13/26760696.html si-local-file:///var/storage/secattach/20260713/26760696.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+13/26760696.html Mon, 13 Jul 2026 09:04:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Corporate+News/Oncolytics+to+meet+FDA+on+registrational+path+for+REO+033+trial/26760655.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced a clinical and regulatory update on its REO 033 trial, a randomized controlled study evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of patients with RAS-mutant, microsatellite stable metastatic colorectal cancer.</p><p>The company said approximately half of the planned clinical sites for Part A of REO 033, which targets 60 patients, will be activated by the end of July 2026, with the remaining sites expected to be activated by the end of August. More than 20 patients have been pre-identified across participating centers. Enrollment at Rutgers Cancer Institute of New Jersey was http://www.streetinsider.com/Corporate+News/Oncolytics+to+meet+FDA+on+registrational+path+for+REO+033+trial/26760655.html Mon, 13 Jul 2026 09:01:13 -0400 ONCY http://www.streetinsider.com/FDA/Oncolytics+to+meet+FDA+on+registrational+path+for+REO+033+trial/26760655.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced a clinical and regulatory update on its REO 033 trial, a randomized controlled study evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of patients with RAS-mutant, microsatellite stable metastatic colorectal cancer.</p><p>The company said approximately half of the planned clinical sites for Part A of REO 033, which targets 60 patients, will be activated by the end of July 2026, with the remaining sites expected to be activated by the end of August. More than 20 patients have been pre-identified across participating centers. Enrollment at Rutgers Cancer Institute of New Jersey was http://www.streetinsider.com/FDA/Oncolytics+to+meet+FDA+on+registrational+path+for+REO+033+trial/26760655.html Mon, 13 Jul 2026 09:01:13 -0400 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html <p align="center"><em>Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers</em></p> <p align="center"><em>Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design</em></p> <p align="center"><em>Part B will be a randomized study designed to support potential accelerated and full approval</em></p> <p align="justify">SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Reports+FDA+Regulatory+Milestone+and+Strong+Clinical+Progress+in+Randomized+RAS-Mutant+MSS+Colorectal+Cancer+Trial/26760610.html Mon, 13 Jul 2026 09:00:00 -0400 A.06822034 O.02608059 O.20026344 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+06/26747837.html si-local-file:///var/storage/secattach/20260708/26747837.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+06/26747837.html Wed, 08 Jul 2026 16:23:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+06/26747837.html si-local-file:///var/storage/secattach/20260708/26747837.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jul+06/26747837.html Wed, 08 Jul 2026 16:23:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+16/26651666.html si-local-file:///var/storage/secattach/20260616/26651666.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+16/26651666.html Tue, 16 Jun 2026 09:05:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+16/26651666.html si-local-file:///var/storage/secattach/20260616/26651666.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+16/26651666.html Tue, 16 Jun 2026 09:05:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Corporate+News/ONCY+secures+U.S.+patent+for+pelareorep+manufacturing+through+2044/26651426.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Patent and Trademark Office has issued a new patent covering the manufacturing process for its investigational immunotherapy pelareorep, with protection expected to extend through 2044.</p> <p>The patent covers key aspects of the methods used to produce pelareorep and is intended to protect the company's ability to manufacture the therapy at commercial scale.</p> <p>The company also noted that a previously filed method-of-use patent application, directed at pelareorep's use as an immunotherapy, remains under review by the USPTO. If issued, that patent is expected to provide protection through 2046.</p> <p>Oncolytics said it plans to file additional http://www.streetinsider.com/Corporate+News/ONCY+secures+U.S.+patent+for+pelareorep+manufacturing+through+2044/26651426.html Tue, 16 Jun 2026 09:00:45 -0400 O.02608059 ONCY http://www.streetinsider.com/Corporate+News/ONCY+secures+U.S.+patent+for+pelareorep+manufacturing+through+2044/26651426.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Patent and Trademark Office has issued a new patent covering the manufacturing process for its investigational immunotherapy pelareorep, with protection expected to extend through 2044.</p> <p>The patent covers key aspects of the methods used to produce pelareorep and is intended to protect the company's ability to manufacture the therapy at commercial scale.</p> <p>The company also noted that a previously filed method-of-use patent application, directed at pelareorep's use as an immunotherapy, remains under review by the USPTO. If issued, that patent is expected to provide protection through 2046.</p> <p>Oncolytics said it plans to file additional http://www.streetinsider.com/Corporate+News/ONCY+secures+U.S.+patent+for+pelareorep+manufacturing+through+2044/26651426.html Tue, 16 Jun 2026 09:00:45 -0400 O.02608059 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html <p align="center"><em>Intellectual property update confirms pelareorep’s unique manufacturing process and scalability</em></p> <p align="center"><em>Previously filed method-of-use patent application expected to provide protection into 2046</em></p> <p align="center"><em>Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate</em></p> <p align="justify">SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html Tue, 16 Jun 2026 09:00:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html <p align="center"><em>Intellectual property update confirms pelareorep’s unique manufacturing process and scalability</em></p> <p align="center"><em>Previously filed method-of-use patent application expected to provide protection into 2046</em></p> <p align="center"><em>Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate</em></p> <p align="justify">SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html Tue, 16 Jun 2026 09:00:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html <p align="center"><em>Intellectual property update confirms pelareorep’s unique manufacturing process and scalability</em></p> <p align="center"><em>Previously filed method-of-use patent application expected to provide protection into 2046</em></p> <p align="center"><em>Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate</em></p> <p align="justify">SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html Tue, 16 Jun 2026 09:00:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html <p align="center"><em>Intellectual property update confirms pelareorep’s unique manufacturing process and scalability</em></p> <p align="center"><em>Previously filed method-of-use patent application expected to provide protection into 2046</em></p> <p align="center"><em>Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate</em></p> <p align="justify">SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Secures+New+U.S.+Patent+Protecting+Commercial+Manufacturing+of+Pelareorep+into+2044/26651376.html Tue, 16 Jun 2026 09:00:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+01++Filed+by%3A+McAdory+John+Bearden/26599483.html si-local-file:///var/storage/secattach/20260603/26599483.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+01++Filed+by%3A+McAdory+John+Bearden/26599483.html Wed, 03 Jun 2026 16:32:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+01++Filed+by%3A+McAdory+John+Bearden/26599483.html si-local-file:///var/storage/secattach/20260603/26599483.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+01++Filed+by%3A+McAdory+John+Bearden/26599483.html Wed, 03 Jun 2026 16:32:00 -0400 O.02608059 ONCY